Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ola Landgren

Showing results (381-390 of 520) with videos related to

Pageof 52
Sort By:
Blood|September 25, 2024
Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myelomaHolly Lee, Michael Durante, Sheri Skerget, et al.
Blood Cancer Journal|May 31, 2022
Structural variants shape the genomic landscape and clinical outcome of multiple myelomaCody Ashby, Eileen M Boyle, Michael A Bauer, et al.
Leukemia Research|January 28, 2014
Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseasesPrashant R Tembhare, Constance M Yuan, David Venzon, et al.
Nature Communications|August 3, 2022
The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory statesLeo Rasche, Carolina Schinke, Francesco Maura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2024
Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple MyelomaDickran Kazandjian, Benjamin Diamond, Marios Papadimitriou, et al.
Blood Advances|November 4, 2022
Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrationsKylee H Maclachlan, Tina Bagratuni, Efstathios Kastritis, et al.
Cancer Immunology Research|May 23, 2019
BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential SynergyEric L Smith, Sham Mailankody, Mette Staehr, et al.
Blood|April 27, 2022
Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphomaMichael D Jain, Bachisio Ziccheddu, Caroline A Coughlin, et al.
NPJ Precision Oncology|October 19, 2022
Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)Nina Nguyen, Sana Chaudhry, Tulasigeri M Totiger, et al.
Biorxiv : the Preprint Server for Biology|August 7, 2023
The Vk*MYC Mouse Model recapitulates human multiple myeloma evolution and genomic diversityFrancesco Maura, David G Coffey, Caleb K Stein, et al.
Pageof 52

Showing results (381-390 of 520) with videos related to

Sort By:
Pageof 52
Blood|September 25, 2024
Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myelomaHolly Lee, Michael Durante, Sheri Skerget, et al.
Blood Cancer Journal|May 31, 2022
Structural variants shape the genomic landscape and clinical outcome of multiple myelomaCody Ashby, Eileen M Boyle, Michael A Bauer, et al.
Leukemia Research|January 28, 2014
Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseasesPrashant R Tembhare, Constance M Yuan, David Venzon, et al.
Nature Communications|August 3, 2022
The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory statesLeo Rasche, Carolina Schinke, Francesco Maura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2024
Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple MyelomaDickran Kazandjian, Benjamin Diamond, Marios Papadimitriou, et al.
Blood Advances|November 4, 2022
Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrationsKylee H Maclachlan, Tina Bagratuni, Efstathios Kastritis, et al.
Cancer Immunology Research|May 23, 2019
BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential SynergyEric L Smith, Sham Mailankody, Mette Staehr, et al.
Blood|April 27, 2022
Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphomaMichael D Jain, Bachisio Ziccheddu, Caroline A Coughlin, et al.
NPJ Precision Oncology|October 19, 2022
Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)Nina Nguyen, Sana Chaudhry, Tulasigeri M Totiger, et al.
Biorxiv : the Preprint Server for Biology|August 7, 2023
The Vk*MYC Mouse Model recapitulates human multiple myeloma evolution and genomic diversityFrancesco Maura, David G Coffey, Caleb K Stein, et al.
Pageof 52